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ABSTRACT
Background Patients with cancer benefit from treatment 
with immune checkpoint inhibitors (ICIs), and those with an 
inflamed tumor microenvironment (TME) and/or high tumor 
mutation burden (TMB), particularly, tend to respond to 
ICIs; however, some patients fail, whereas others acquire 
resistance after initial response despite the inflamed TME 
and/or high TMB. We assessed the detailed biological 
mechanisms of resistance to ICIs such as programmed 
death 1 and/or cytotoxic T- lymphocyte- associated protein 
4 blockade therapies using clinical samples.
Methods We established four pairs of autologous tumor 
cell lines and tumor- infiltrating lymphocytes (TILs) from 
patients with melanoma treated with ICIs. These tumor cell 
lines and TILs were subjected to comprehensive analyses 
and in vitro functional assays. We assessed tumor volume 
and TILs in vivo mouse models to validate identified 
mechanism. Furthermore, we analyzed additional clinical 
samples from another large melanoma cohort.
Results Two patients were super- responders, and the 
others acquired resistance: the first patient had a non- 
inflamed TME and acquired resistance due to the loss of the 
beta- 2 microglobulin gene, and the other acquired resistance 
despite having inflamed TME and extremely high TMB which 
are reportedly predictive biomarkers. Tumor cell line and 
paired TIL analyses showed high CD155, TIGIT ligand, and 
TIGIT expression in the tumor cell line and tumor- infiltrating 
T cells, respectively. TIGIT blockade or CD155- deletion 
activated T cells in a functional assay using an autologous 
cell line and paired TILs from this patient. CD155 expression 
increased in surviving tumor cells after coculturing with TILs 
from a responder, which suppressed TIGIT+ T- cell activation. 
Consistently, TIGIT blockade or CD155- deletion could aid 
in overcoming resistance to ICIs in vivo mouse models. In 
clinical samples, CD155 was related to resistance to ICIs in 
patients with melanoma with an inflamed TME, including 
both primary and acquired resistance.
Conclusions The TIGIT/CD155 axis mediates resistance 
to ICIs in patients with melanoma with an inflamed TME, 
promoting the development of TIGIT blockade therapies in 
such patients with cancer.
BACKGROUND
Cancer acquires mechanisms to escape the 
immune system during development and 
progression.1 2 One such mechanism involves 
the induction of inhibitory molecules, such 
as programmed death 1 (PD- 1)/PD- 1 ligands 
and cytotoxic T- lymphocyte- associated protein 
4 (CTLA- 4).1–4 Immune checkpoint inhibitors 
(ICIs) against these molecules improve the 
outcome of various types of cancer including 
melanoma and lung cancer.5–7 However, their 
efficacy as monotherapy is unsatisfactory, with 
a response rate of less than 50%.
PD- 1, which interacts with PD- 1 ligands, is 
primarily expressed following the activation of 
T cells and suppresses T cell function, falling 
T cells into a dysfunctional exhausted state.8 9 
ICIs reinvigorate dysfunctional exhausted T 
cells, leading to tumor regression.10–14 Thus, 
the inflamed tumor microenvironment 
(TME) (ie, highly CD8+ T- cell- infiltrated 
TME) is a predictive biomarker of ICIs.11–14 
Another well- known predictive biomarker 
is the tumor mutation burden (TMB).13–16 
Since neoantigens derived from somatic 
mutations induce strong immune responses 
as non- self- antigens, patients with high TMB, 
which reflect a high number of neoantigens, 
reportedly respond favorably to ICIs.10 15 16 
However, the efficacy of ICIs remains inad-
equate even when these biomarkers are 
present.13 14 Indeed, several controversies 
have been reported.13 14 17 In particular, some 
patients with inflamed TME and/or high 
TMB fail to respond to ICIs in clinical settings.
It is important to elucidate the resistance 
mechanisms to identify biomarkers and 
increase the efficacy of the treatment.18 19 
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Patients resistant to ICIs can be divided into two groups: 
those who primarily fail to respond (primary resistance) 
and those who initially respond but eventually develop 
disease progression (acquired resistance).18 19 There are 
several known mechanisms such as non- inflamed TME, 
lack of sufficient or suitable neoantigens, loss- of- function 
genomic alterations in interferon (IFN)-γ signaling path-
ways, loss of beta- 2 microglobulin (B2M) subunit of major 
histocompatibility complex class I (MHC- I), and upreg-
ulation of other inhibitory checkpoint molecules.18–23 
However, the mechanisms of both primary and acquired 
resistance to ICIs have not been fully understood, which 
may be due to the complexity of human cancer and also of 
the immune system. In addition, heterogeneous human 
clinical samples appear to be significantly different from 
homogeneous animal models. Thus, further research 
using human clinical samples is warranted.
Here, we established four pairs of tumor cell lines and 
cultured tumor- infiltrating lymphocytes (TILs) from four 
patients with melanoma who received ICIs. Two were 
super- responders, and the remaining two acquired resis-
tance after the initial response. Pathological analyses, 
whole- exome sequencing (WES), and RNA sequencing 
(RNA- seq) showed that a patient acquired resistance 
despite an inflamed TME and extremely high TMB. Using 
comprehensive analyses and functional assays, we iden-
tified that the TIGIT/CD155 axis, one of the inhibitory 
molecules,24–26 contributed to the acquired resistance. In 
another melanoma cohort, CD155 was related to resis-
tance to ICIs in patients with inflamed TME, including 
both primary and acquired resistance. We propose 
that the TIGIT/CD155 axis mediates resistance to ICIs 
in patients with cancer with inflamed TME, including 
acquired resistance, and that TIGIT blockade therapies 
should be developed for such patients.
MATERIALS AND METHODS
Patients and samples
Four patients with melanoma who underwent surgical 
resection at Yamanashi University Hospital from 2017 to 
2019, were enrolled in this study to establish autologous 
tumor cell lines and cultured TILs (online supplemental 
table S1). All participants provided written informed 
consent. Tumor specimens collected from the patients 
were processed as previously described.23 Briefly, surgically 
resected tumors were enzymatically digested with colla-
genase, hyaluronidase, and deoxyribonuclease (Sigma- 
Aldrich, St. Louis, Missouri, USA) in RPMI1640 (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) at room 
temperature. After filtration and separation according to 
density gradient, the digested tumors were used.
In addition to these patients, 144 patients with mela-
noma treated with anti- PD- 1 monoclonal antibody (mAb) 
and/or anti- CTLA- 4 mAb whose formalin- fixed, paraffin- 
embedded (FFPE) tissues were available at Yamanashi 
University Hospital, Chiba University Hospital, Shinshu 
University Hospital, Saitama Medical University 
International Medical Center, Okayama University 
Hospital, and Kumamoto University Hospital from 2014 
to 2020 were enrolled in this study as another cohort 
(online supplemental tables 2 and 3). Patients who 
received ICIs as second- line therapies received BRAF/
MEK inhibitors before ICIs, and their samples were 
obtained before treatment with BRAF/MEK inhibitors. If 
available, we also obtained both pretreatment and post- 
treatment paired samples from patients who developed 
resistance after treatment. Patients’ clinical information 
was obtained from their medical records.
In vitro expansion of TILs
TILs were cultured and expanded as previously 
described.23 In brief, melanoma tumor digests were initi-
ated in RPMI1640 supplemented with 10% human AB 
serum, antibiotics, and recombinant human interleukin 
2 (rhIL- 2: 6000 IU/mL, PeproTech, Cranbury, New Jersey 
USA) in a humidified 37°C incubator with 5% CO2. Half 
of the media was aspirated from the wells and replaced 
with fresh complete medium and rhIL- 2 every 2–3 days.
Cell lines
To establish tumor cell lines, 1×107 digested tumor cells 
were cultured in RPMI1640, containing 10% fetal bovine 
serum (FBS; Cytiva, Tokyo, Japan), penicillin, strepto-
mycin, and amphotericin B (Thermo Fisher Scientific). 
Tumor cells were passaged at approximately 80%–90% 
confluence and used when free of fibroblasts and 
proliferating beyond the 10th passage. The MEL01 cell 
line was generated from a previously reported patient 
with melanoma who acquired resistance after an initial 
response to PD- 1 blockade.23 This cell line lost the B2M 
gene and had no MHC class I expression.23 Both MEL02 
and MEL03 cell lines were generated from melanoma 
super- responders to PD- 1 blockade before the initiation 
of therapy. The MEL04 cell line was generated from a 
patient with melanoma who acquired resistance to anti- 
PD- 1 and anti- CTLA- 4 mAbs after initial response to anti- 
PD- 1 mAb (online supplemental table S1 and figure S1).
B16F10 (mouse melanoma) and EMT6 (mouse breast 
cancer) cell lines were purchased from ATCC (Manassas, 
Virginia, USA) and were maintained in the RPMI1640 
medium supplemented with 10% FBS. All tumor cells 
were used after confirming that they were Mycoplasma (−) 
after Mycoplasma testing with the PCR Mycoplasma Detec-
tion Kit (TaKaRa, Shiga, Japan) according to the manu-
facturer’s instructions.
WES
Genomic DNA was isolated from each melanoma cell line 
and paired peripheral blood using a QIAamp DNA Mini 
Kit (QIAGEN, Hulsterweg, Netherlands) and enriched 
for exonic fragments using the SureSelect Human All 
Exon Kit v6 (Agilent Technologies, Santa Clara, Cali-
fornia, USA). Massive parallel sequencing of the isolated 
fragments was performed with the HiSeq3000 instru-
ment (Illumina, San Diego, California, USA) using the 
3Kawashima S, et al. J Immunother Cancer 2021;9:e003134. doi:10.1136/jitc-2021-003134
Open access
paired- end method. WES reads that masked nucleotides 
with a quality value of <20 were independently aligned to 
the human reference genome (hg38) using BWA (http:// 
bio- bwa. sourceforge. net/) and Bowtie2 (http:// bowtie- 
bio. sourceforge. net/ bowtie2/ index. shtml). Both somatic 
synonymous and non- synonymous mutations were called 
using our in- house caller and two publicly available muta-
tion callers: Genome Analysis Toolkit (https:// gatk. broa-
dinstitute. org/ hc/ en- us) MuTect2 and VarScan2 (http:// 
varscan. sourceforge. net/). Mutations were discarded 
if any of the following criteria were met: the total read 
number was <20, the variant allele frequency (VAF) in the 
tumor samples was <0.05, the mutant read number in the 
germline control samples was >2, the mutation occurred 
in only one strand of the genome, or the variant was 
present in the normal human genome in either the 1000 
Genomes Project data set (https://www. internationalge-
nome. org/) or our in- house database. Gene mutations 
were annotated using SnpEff (https:// pcingola. github. 
io/ SnpEff/). Copy number status was analyzed using 
our in- house pipeline, which determines the logR ratio 
(LRR) as follows: (1) Single nucleotide polymorphism 
(SNP) positions in the 1000 Genomes Project database 
that were in a homozygous state (VAF≤0.05, or ≥0.95) or 
a heterozygous state (VAF=0.4–0.6) in the genomes of 
respective normal samples were selected; (2) normal and 
tumor read depths at the selected position were adjusted 
based on the G+C percentage of a 100 bp window flanking 
the position; (3) the LRR was calculated as  log2
ti
ni  , where  ni  
and  ti  are the normal and tumor- adjusted depths at posi-
tion i, respectively, and (4) each representative LRR was 
determined as the median of a moving window (1 Mb) 
centered at position  i .
RNA-seq and expression analysis
Total RNA was extracted from each melanoma cell line 
using the RNeasy Mini Kit (Qiagen). RNA- seq libraries 
were prepared using the NEBNext Ultra RNA Library 
Prep Kit (New England BioLabs, Ipswich, Massachu-
setts, USA), in which complementary DNA (cDNA) 
was prepared from polyA- selected RNA. The prepared 
RNA- seq libraries were subjected to next- generation 
sequencing from both ends (paired- end reads). The 
expression level of each gene was calculated using 
DESeq2 (http:// bioconductor. org/ packages/ release/ 
bioc/ html/ DESeq2. html) with variance- stabilizing trans-
formation (VST) .
Principal component analysis and gene set enrichment 
analysis
Principal component analysis (PCA) based on the top 
10,000 variable genes was performed using R software (R 
Foundation for statistical computing). Enriched pathways 
were determined using the gene set enrichment analysis 
(GSEA) tool available on the Broad Institute website. 
Hallmark gene sets were downloaded from the MSigDB 
database.27
Quantitative real-time reverse transcription polymerase chain 
reaction (qRT-PCR)
Total RNA was reverse- transcribed to cDNA using Prime-
Script RT Master Mix (TaKaRa), and real- time PCR was 
performed using TB Green Premix Ex Taq II (TaKaRa) 
according to the manufacturer’s instructions. GAPDH 
was used as internal control. The experiments were 
performed in triplicate. The primers used are listed in 
online supplemental table S4.
Human PVR-deletion or mouse pvr-deletion using CRISPR/
Cas9 technology
Human PVR- knockout (KO) MEL04, mouse pvr- KO 
B16F10, and EMT6 cell lines were generated using 
CRISPR/Cas9 technology. Briefly, a targeting guide 
RNA (gRNA) sequence (human, 5ʹ- CGTTTGGACTC-
CGAATAGCT- 3ʹ; mouse, 5ʹ- TCAAATAACCTGGATGAA-
GA- 3ʹ) was used to edit the genomic locus. The gRNA and 
Cas9 protein (Thermo Fisher Scientific) were transfected 
into MEL04, B16F10, or EMT6 cells using lipofectamine 
CRISPRMAX (Thermo Fisher Scientific). The expression 
of CD155 was evaluated using flow cytometry in triplicate.
IFN-γ release functional assay
Cultured autologous tumor cell lines (105 cells/well) were 
used as stimulator cells. TILs (105 cells/well) were added 
to the tumor cells, and were incubated for 24 hours. 
The supernatants were assayed with ELISA for IFN-γ 
(Thermo Fisher Scientific). Anti- TIGIT mAb (MBSA43, 
Thermo Fisher Scientific), anti- LAG- 3 mAb (11C3C65, 
BioLegend, San Diego, California, USA), anti- TIM- 3 mAb 
(F38- 2F2, BioLegend), and anti- MHC- I mAb (W6/32, 
BioLegend) were added at a concentration of 10 µg/mL. 
In vitro experiments were performed in triplicates.
TIGIT expression analyses by cultured T cells
Autologous tumor cells were cocultured with paired 
TILs for 48 hours, and subsequently, TIGIT expression 
was analyzed with flow cytometry. In addition, TILs or 
peripheral blood mononuclear cells (PBMCs) from 
healthy donors were stimulated by anti- CD3 mAb (OKT3, 
Thermo Fisher Scientific) at indicated concentrations 
and anti- CD28 mAb (CD28.8, Thermo Fisher Scientific) 
at 0.5 µg/mL. Forty- eight hours later, TIGIT expression 
was analyzed with flow cytometry. In vitro experiments 
were performed in triplicates.
In vivo animal study
Female C57BL/6J mice (6–8 weeks old) were purchased 
from CLEA Japan (Tokyo, Japan). C57BL/6J- 
Prkdc<scid>/Rbrc mice (B6 SCID; RBRC01346) were 
provided by RIKEN BRC (Tsukuba, Japan) through the 
National BioResource Project of the MEXT/AMED, 
Japan. Cells (1×106) were injected subcutaneously, and 
the tumor volume was monitored two times a week. The 
mean values of the long and short diameters were used to 
generate tumor growth curves. Mice were grouped when 
the tumor volume reached approximately 100 mm3, and 
ICIs (anti- PD- 1 mAb, 200 µg/mouse; anti- CTLA- 4 mAb, 
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100 µg/mouse; anti- TIGIT mAb, 100 µg/mouse) were 
administered intraperitoneally three times every 3 days 
thereafter. Tumors were harvested 7 days after treatment 
initiation to collect TILs for evaluation. Rat anti- mouse 
PD- 1 mAb (RMP1- 14) were purchased from BioXcell 
(West Lebanon, New Hampshire, USA). Mouse anti- 
mouse CTLA- 4 mAb (9D9- IgG2a) and mouse anti- mouse 
TIGIT mAb (1B4) were purchased from absolute anti-
body (Oxford, UK). In vivo experiments were performed 
at least two times. All mice were maintained under 
specific pathogen- free conditions at the animal facility 
of the Institute of Biophysics. Mouse experiments were 
approved by the Animal Committee for Animal Experi-
mentation of the Chiba Cancer Center. All experiments 
met the US Public Health Service Policy on the Humane 
Care and Use of Laboratory Animals.
Flow cytometry analyses
Flow cytometry assays were performed as previously 
described.28 Briefly, cells were washed with phosphate- 
buffered saline containing 2% FBS and stained with 
surface antibodies. Intracellular staining was performed 
with specific antibodies and the FOXP3/Transcription 
Factor Staining Buffer set (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. For intra-
cellular cytokine staining, the GolgiPlug reagent (BD 
Biosciences) was added for the last 4 hours of culture. 
Samples were assessed with BD Canto II or BD FACSVerse 
and FlowJo software (BD Biosciences). The staining anti-
bodies were diluted according to the manufacturer’s 
instructions. The antibodies used in flow cytometry are 
listed in online supplemental table S5.
Immunohistochemistry
Sections of FFPE tissue (3 µm) were dried, dewaxed, 
and rehydrated. Immunohistochemical staining for 
both CD8 and CD155 was performed automatically 
using the Ventana XT system BenchMark (Ventana 
Medical Systems, Tucson, Arizona, USA), as previously 
described.29 Briefly, the tissue sections were automatically 
treated with an antigen retrieval solution (Ventana) and 
heated on a slide heater at 100°C for 30 min. Endoge-
nous peroxidase activity was quenched by immersion in 
3% hydrogen peroxide for 4 min. The sections were then 
incubated with anti- CD8 mAb (CB/144B, Dako, 1/100 
dilution) or anti- CD155 mAb (D3G7H, Cell Signaling 
Technology, 1/500 dilution) for 30 min at 37°C. Detec-
tion was performed using the LSAB Ventana Iview DAB 
detection system (Ventana) according to the manufac-
turer’s instructions. The sections were counterstained 
with hematoxylin and blindly reviewed by pathologists 
(TKawas and YI). Membrane expression of CD155 in 
tumor cells was assessed as previously reported.30 Intra-
tumoral CD8+ T cells were counted: five fields 0.25 mm2 
were randomly selected and counted for each slide as 
previously reported.31 For each patient, the mean value 
of the counts in five areas was used for the statistical anal-
ysis. We set cut- offs for CD8 count and CD155 score from 
the receiver operating characteristic (ROC) curves using 
6- month progression- free survival (PFS).
Statistical analyses
GraphPad Prism V.8 (GraphPad Software), JMP Pro 
V.16.0 (SAS Institute), or R V.4.0.2, was used for statistical 
analyses. Patients’ characteristics were compared between 
two groups using the Fisher’s exact test. The relationships 
of continuous variables between or among groups were 
compared using the t- test or one- way analysis of variance 
(ANOVA), respectively. The relationships between tumor 
volume curves were compared using two- way ANOVA. For 
multiple testing, Bonferroni corrections were employed. 
PFS and overall survival (OS) were defined as the time 
from the initiation of first ICIs until the first observation 
of disease progression or death from any cause and the 
time from the initiation of first ICIs until death from 
any cause, respectively. PFS and OS were analyzed using 
a Kaplan- Meier method and compared among groups 
using a log- rank test. A Cox proportional hazards model 
was used for the univariate and multivariate analyses to 
estimate HRs and 95% CIs. P values <0.05 were consid-
ered statistically significant.
RESULTS
A patient with melanoma acquired resistance to ICIs despite 
the inflamed TME and extremely high TMB
A man in his early 70s (MEL04) with cutaneous mela-
noma received anti- PD- 1 mAb monotherapy as first- line 
therapy and achieved partial response (online supple-
mental figure S1A). Thirty months later, however, he 
acquired resistance and had brain and subcutaneous 
metastases. Anti- CTLA- 4 mAb was added but he failed to 
respond (online supplemental figure S1A). The subcu-
taneous lesion was resected. Pathological analyses of the 
resected lesion revealed that tumor- infiltrating CD8+ T 
cells increased after the treatment, which is different from 
that in a previously reported patient with melanoma who 
acquired resistance due to loss of the B2M gene (MEL01) 
(online supplemental figure S1B and table S1).23 Accord-
ingly, MHC- I was highly expressed in MEL04 tumor cells 
(online supplemental figure S1C).
Next, we performed WES and RNA- seq using four 
melanoma cell lines from two responders (MEL02 and 
MEL03) and two non- responders (acquired resistance) 
(MEL01 and MEL04) to ICIs (online supplemental 
table S1). Representative driver oncogene alterations 
and TMB are summarized in figure 1A, which show that 
MEL04 had an extremely high TMB. PCA using RNA- 
seq data showed that the MEL04 cell line was different 
from MEL01, although both were acquired- resistance cell 
lines. In contrast, the MEL04 cell line was similar to the 
responders’ MEL02 and MEL03 cell lines (figure 1B). 
Next, we performed GSEA to identify differences between 
MEL01 and MEL02, MEL03, and MEL04, resulting in 
the enrichment of immune- related gene signatures 
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(figure 1C). Altogether, MEL04 acquired resistance to 
ICIs despite the inflamed TME and extremely high TMB.
TIGIT/CD155 axis mediates resistance to immunotherapy
In general, both inflamed TME and high TMB are well- 
known predictive biomarkers for ICIs, which is incon-
sistent with MEL04.10–16 These findings prompted us to 
analyze immune suppressive factors, especially co- inhib-
itory checkpoint molecules other than PD- 1 or CTLA- 4. 
Among the co- inhibitory checkpoint molecules from 
RNA- seq, the MEL04 cell line showed high expression 
of LGALS9, PVR, and NECTIN2 (encoding Galectin9, 
CD155, and CD112, respectively) compared with the 
other cell lines (online supplemental figure S1D). We 
validated the results using qRT- PCR and flow cytometry, 
which showed that CD155, a TIGIT ligand, was highly 
expressed only in MEL04 cells (figure 2A,B, and online 
supplemental figure S1E). Next, we analyzed immune 
checkpoint molecules expressed in tumor- infiltrating 
T cells before expansion in these four patients. Accord-
ingly, TIGIT was particularly highly expressed in tumor- 
infiltrating T cells of MEL04 (figure 2C). These findings 
suggest that MEL04 could confer resistance to ICIs due to 
the TIGIT/CD155 axis.
To validate the role of the TIGIT/CD155 axis in the 
resistance mechanism of MEL04, we performed an IFN-γ 
release functional assay using pairs of autologous tumor 
cell lines and TILs from the same patients. A pair from 
MEL02 was used as a control since the cell line and 
TILs had low CD155 and low TIGIT expression, respec-
tively. IFN-γ released by coculturing with the MEL02 
cell line and TILs was not increased by TIGIT blockade 
(figure 2D). In contrast, IFN-γ release was increased by 
TIGIT blockade but not by the others (LAG- 3 and TIM- 3) 
in MEL04 (figure 2D). These results are consistent with 
high TIGIT but low LAG- 3 and TIM- 3 expression in 
tumor- infiltrating T cells in MEL04 (figure 2C). Next, 
we created the PVR- KO MEL04 cell line using CRISPR/
Cas9 technology and performed a similar functional assay 
(figure 2E). Consistently, PVR- deletion increased IFN-γ 
release, and the addition of the TIGIT blockade had 
no effect (figure 2F). These findings indicate that the 
TIGIT/CD155 axis mediates resistance to ICIs in CD155- 
expressing tumors with tumor- infiltrating TIGIT+ T cells.
Tumor cells acquire resistance to immunotherapy through the 
TIGIT/CD155 axis
We established an acquired resistance model using the 
pair of MEL02 cell line and TILs (figure 3A). Surviving 
tumor cells and TILs after coculture had higher CD155 
and TIGIT expression than the controls (figure 3B–E). 
Similarly, anti- CD3 mAb increased TIGIT expression in 
CD8+ T cells in a dose- dependent manner (figure 3F,G, 
and online supplemental figure S2), indicating that 
T- cell receptor (TCR) signaling pathways increase 
TIGIT expression. In addition, TIGIT is reportedly 
Figure 1 MEL04 involving inflamed tumor microenvironment and extremely high TMB. (A) TMB and representative driver 
gene alterations in four melanoma cell lines. Whole- exome sequencing was performed for each cell line. The number of non- 
synonymous mutations and representative driver gene alterations of melanoma are shown. (B) PCA in four melanoma cell lines. 
We conducted a PCA based on variable gene expression (top 10,000 SD) from the RNA- sequencing data. (C) Immune- related 
gene signatures from gene set enrichment analysis in MEL02, 03, and 04 compared with MEL01. Interferon-α, interferon-γ, and 
inflammatory response related gene signatures from the MSigDB database are shown. PCA, principal component analysis; 
TMB, tumor mutation burden.
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considered a chronically stimulated exhausted T cell 
marker.8 9 To imitate chronic stimulation, we also cocul-
tured for 1 month exchanging TILs every week, showing 
that surviving tumor cells had high CD155 expression 
(online supplemental figure S3). Accordingly, surviving 
CD155- expressing MEL02 tumor cells suppressed T- cell 
activation, which was canceled by TIGIT blockade 
(figure 3H). Since PD- 1 reportedly inhibits TCR signaling 
Figure 2 The TIGIT/CD155 axis mediates resistance to immunotherapy from functional assays using clinical samples. (A and 
B) Expression of TIGIT, LAG- 3, and TIM- 3 ligands in tumor cells. We selected CD155 and CD112 as TIGIT ligands, galectin- 3, 
and MHC class II (MHC- II) as LAG- 3 ligands, and galectin- 9 as a TIM- 3 ligand. Representative flow cytometry staining (A) and 
summaries (B) are shown. (C) TIGIT, LAG- 3, and TIM- 3 expression in tumor- infiltrating T cells. Surgically resected tumors were 
digested, and the digested products before culture and expansion were subsequently analyzed with flow cytometry. (D) IFN-γ 
release assay of MEL02 (left) and MEL04 (right). Autologous tumor cells and paired TILs were cocultured with or without each 
immune checkpoint inhibitors for 24 hours. Supernatants were analyzed with ELISA for IFN-γ. Anti- MHC- I mAb was used for 
a negative control. Fold changes to samples with control mAb are shown. (E) CD155 expression in MEL04 tumor cells. The 
PVR gene was knocked out in the MEL04 cell line using CRISPR/Cas9 technology (PVR- KO), and the created cell line was 
analyzed by flow cytometry. Representative flow cytometry staining from triplicated experiments is shown. (F) IFN-γ release 
assay of MEL04. In vitro experiments were performed as described in (D). All in vitro experiments were performed in triplicate, 
and one- way analysis of variance with Bonferroni corrections were used in (B), (D), and (F) for statistical analyses. The means 
and SEM are shown. ****, p<0.0001; ns, not significant; IFN-γ, interferon-γ; MFI, mean fluorescent intensity; TIL, tumor- infiltrating 
lymphocyte.
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pathways, PD- 1 blockade activates these pathways.32 Alto-
gether, TCR signaling pathways, which can be activated 
by PD- 1 blockade, increase TIGIT expression in effector 
T cells, and TIGIT+ effector T cells are suppressed by 
CD155 expressed in tumor cells, resulting in the survival 
of CD155- expressing tumor cells and acquired resistance.
TIGIT/CD155 blockade overcomes resistance to ICIs in in vivo 
mouse models
We performed in vivo mouse experiments using CD155- 
expressing mouse cell lines; furthermore, expression 
of another TIGIT ligand, CD112, in these cell lines was 
comparable (figure 4A and online supplemental figure 
S4A). These tumors were resistant to combination with 
anti- PD- 1 and anti- CTLA- 4 mAbs (figure 4B and online 
supplemental figure S4B). TIGIT was highly expressed 
in tumor- infiltrating CD8+ T cells from treated mice 
compared with that in the control (figure 4C,D). Addi-
tion of anti- TIGIT mAb aided in overcoming the resis-
tance (figure 4E and online supplemental figure S4B). 
Furthermore, the addition of TIGIT blockade to PD- 1 
or CTLA- 4 blockade partially overcame the resistance 
(figure 4E and Supplementary Figure S4B). In contrast, 
Figure 3 The TIGIT/CD155 axis induces acquired resistance to immunotherapy. (A) Graphical experimental schema of the 
in vitro acquired resistance model. Autologous tumor cells were cocultured with paired TILs for 48 hours, and both were 
subsequently analyzed with flow cytometry. In addition, CD155- expressing tumor cells were sorted and subjected to functional 
assay. (B–E) CD155 expression in MEL02 tumor cells and TIGIT expression in tumor- infiltrating T cells from MEL02. Expression 
was analyzed 48 hours after coculture as described in (A). Representative flow cytometry staining (B, tumor cells; D, tumor- 
infiltrating T cells) and summaries of MFI (C, tumor cells; E, tumor- infiltrating T cells) are shown. (F and G) TIGIT expression 
in tumor- infiltrating T cells from MEL02. MEL02 TILs were stimulated by anti- CD3 mAb with indicated concentrations and 
anti- CD28 mAb for 48 hours and were subsequently analyzed with flow cytometry. Representative flow cytometry staining (F) 
and summary of MFI (G) are shown. (H) IFN-γ release assay. CD155- or CD155+ autologous tumor cells and paired TILs from 
MEL02 were cocultured with or without anti- TIGIT mAb for 24 hours. Supernatants were analyzed with ELISA for IFN-γ. Fold 
changes to CD155− tumor cells with control mAb are shown. All in vitro experiments were performed in triplicate, and one- way 
analysis of variance with Bonferroni corrections were used in (C), (E), (G), and (H) for statistical analyses. The means and SEM 
are shown. ****, p<0.0001; ns, not significant; hr, hour; IFN-γ, interferon γ; MFI, mean fluorescent intensity; TILs, tumor- infiltrating 
lymphocytes.
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Figure 4 TIGIT blockade overcomes resistance to ICIs in vivo mouse models. (A) CD155 and CD112 expression in B16F10 
cells. Representative flow cytometry staining from triplicated experiments are shown. Gray, isotype. (B) Tumor growth 
treated with combination treatment of anti- PD- 1 and anti- CTLA- 4 mAbs. Cells (1×106) were injected subcutaneously (n=5 
per each group), and tumor volume was monitored two times a week. Mice were grouped when the tumor volume reached 
approximately ~100 mm3, and ICIs were administered intraperitoneally three times every 3 days thereafter. (C and D) TIGIT 
expression in tumor- infiltrating CD8+ T cells. Tumors were harvested 7 days after treatment initiation to collect TILs for 
evaluation. Representative flow cytometry staining (C) and summary (D) are shown. (E) Tumor growth treated with combination 
treatment of anti- PD- 1, anti- CTLA- 4, and anti- TIGIT mAbs. In vivo experiments were performed as described in (B). (F and G) 
The frequencies of CD44+CD62L− effector memory, and cytokine- producing CD8+ T cells in the TME. TILs were analyzed as 
described in (C and D). Representative flow cytometry staining (F) and summaries (G) are shown. All in vivo experiments were 
performed in duplicates, with similar results. A two- way ANOVA was used in (B), a t- test was used in (D), two- way ANOVA 
with Bonferroni corrections were used in (E), and one- way ANOVA with Bonferroni corrections were used in (G) for statistical 
analyses. The means and SEM are shown. *, p<0.05; **, p<0.01; ****, p<0.0001; ANOVA, analysis of variance; CTLA- 4, cytotoxic 
T- lymphocyte- associated protein 4; ICIs, immune checkpoint inhibitors; ns, not significant; PD- 1, programmed death 1; TILs, 
tumor- infiltrating lymphocytes; TME, tumor microenvironment.
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the antitumor effect of ICIs was not observed in B6 SCID 
immunodeficient mice (online supplemental figure 
S4C). Accordingly, addition of anti- TIGIT mAb increased 
the proportion of effector memory CD8+ T cells, as well 
as cytokine production in tumor- infiltrating CD8+ T cells 
(figure 4F,G).
Next, pvr- KO B16F10 and EMT6 cell lines were created 
using CRISPR/Cas9 technology (figure 5A and online 
supplemental figure S4D), and similar in vivo exper-
iments were performed. Pvr- KO tumors grew slightly 
slower than wild- type tumors, and combination with 
anti- PD- 1 and anti- CTLA- 4 mAbs inhibited pvr- KO tumor 
growth (figure 5B and online supplemental figure S4E). 
In contrast, there was no significant difference in tumor 
growth between wild- type and pvr- KO tumors, and anti-
tumor efficacy of ICIs was not observed in B6 SCID 
immunodeficient mice (online supplemental figure S4F). 
Consistently, the proportion of effector memory CD8+ T 
cells, as well as cytokine production in tumor- infiltrating 
CD8+ T cells increased with pvr- deletion (figure 5C,D). 
These findings indicate that the TIGIT/CD155 axis 
mediates resistance to ICIs in in vivo mouse models, 
which can be overcome by TIGIT/CD155 blockade.
CD155 contributes to primary and acquired resistance to ICIs 
in patients with melanoma with inflamed TME
We analyzed additional clinical samples from 144 patients 
with melanoma who received ICIs (online supplemental 
table S2). We included 13 patients who received ICIs 
as second- line therapy in our analyses (online supple-
mental table S2). They have received BRAF/MEK inhib-
itors prior to ICIs, and their pretreatment samples were 
obtained before treatment with BRAF/MEK inhibitors. 
The PFS of patients receiving ICIs as second- line therapy 
was significantly shorter than that of patients as first- 
line therapy, as previously reported33 (online supple-
mental figure S5A). In Japan, acral and mucosal types 
are dominant,34 and our study also included 81 patients 
with these types (online supplemental table S2). While 
acral and mucosal melanomas reportedly have a non- 
inflamed TME with less efficacy of ICIs,35–37 a Japanese 
prospective observational study has shown that anti- PD- 1 
Figure 5 CD155- deletion overcomes resistance to ICIs in vivo mouse model. (A) CD155 expression in pvr- KO B16F10 cells. 
Representative flow cytometry staining from triplicated experiments are shown. (B) Tumor growth treated with combination 
treatment of anti- PD- 1 and anti- CTLA- 4 mAbs. Cells (1×106) were injected subcutaneously (n=5 per each group), and tumor 
volume was monitored two times a week. Mice were grouped when the tumor volume reached approximately ~100 mm3, and 
ICIs were administered intraperitoneally three times every 3 days thereafter. (C and D) The frequencies of CD44+CD62L− effector 
memory, and cytokine- producing CD8+ T cells in the tumor microenvironment treated with combination treatment of anti- PD- 1 
and anti- CTLA- 4 mAbs. Tumors were harvested 7 days after treatment initiation to collect tumor- infiltrating lymphocytes for 
evaluation. Representative flow cytometry staining (C) and summaries (D) are shown. All in vivo experiments were performed in 
duplicates, with similar results. Two- way analysis of variance with Bonferroni corrections were used in (B), and t- tests were used 
in (D) for statistical analyses. The means and SEM are shown. ***, p<0.001; ****, p<0.0001; CTLA- 4, cytotoxic T- lymphocyte- 
associated protein 4; ns, not significant; PD- 1, programmed death 1.
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mAb exhibits similar efficacy against these types.34 We 
analyzed our cohort according to the type and found that 
the OS of patients with acral or mucosal melanoma was 
slightly shorter than that of the others (online supple-
mental figure S5B), which is consistent with previous 
studies.35–37 Next, we stained the FFPE samples for CD8 
and CD155 before ICI treatment (online supplemental 
figure S6A). We set a cut- off for CD8 count and CD155 
score, which was <82.8/≥82.8 and 0–1/2–3, respectively, 
from the ROC curves using 6- month PFS (online supple-
mental figure S6B). There was no significant difference 
in CD8+ T- cell infiltration and CD155 expression among 
melanoma types (online supplemental table S2). Patients 
with high CD8+ T- cell infiltration had significantly longer 
PFS and OS than those with low CD8+ T- cell infiltration, 
which is consistent with the results of previous reports 
(online supplemental figure S6C).11 38 39 Additionally, 
patients with high CD155 expression tended to have a 
worse prognosis, as previously reported (online supple-
mental figure S6D).30 We next divided these patients 
into four groups: CD8 low/CD155 low (n=39), CD8 
low/CD155 high (n=34), CD8 high/CD155 low (n=41), 
and CD8 high/CD155 high (n=30). Patients with CD8 
high/CD155 low had significantly longer PFS and OS 
from other patients, whereas patients with CD8 high/
CD155 high had significantly shorter PFS and OS than 
those with CD8 high/CD155 low and comparable with 
those with CD8 low (figure 6A). This good prognosis 
group (CD8 high/CD155 low) included 19 cutaneous or 
primary unknown and 22 acral or mucosal melanomas, 
respectively (19/63 vs 22/81, p=0.69). Consistently, the 
multivariate analyses demonstrated that immune status 
(CD8 high/CD155 low vs others), but not either treat-
ment line or melanoma type, was an independent prog-
nostic factor in our cohort (online supplemental table 
S6).
Figure 6 CD155 expression is related to resistance to ICIs in patients with melanoma with inflamed tumor microenvironment, 
including acquired resistance. (A) Survival curves of patients with melanoma. We analyzed a prognosis in 144 patients with 
melanoma who received ICIs. PFS and OS were defined as the time from the initiation of first ICIs until the first observation 
of disease progression or death from any cause and the time from the initiation of first ICIs until death from any cause, 
respectively. Survival curves according to CD8+ T- cell infiltration and CD155 expression are shown. (B and C) CD155 staining in 
MEL04 and CD155 expression change from baseline to resistance state. We stained paired formalin- fixed, paraffin- embedded 
samples at both baseline (before ICI) and resistance state (after ICI) in 25 patients with melanoma who received ICIs, and 
evaluated their staining as scores (0, 1+, 2+, and 3+). In addition to all 25 patients, the CD155 expression change was also 
analyzed according to CD8+ T- cell infiltration at resistance state. CD155 staining in MEL04 (B) and the summary of changes (C) 
are shown. Survival curves were analyzed using the Kaplan- Meier method and compared among groups using the log- rank test 
in (A), and paired t- tests were used in (C) for statistical analyses. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; ICIs, immune 
checkpoint inhibitors; ns, not significant; OS, overall survival; PFS, progression- free survival.
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We also obtained both pretreatment and post- treatment 
paired samples from 25 patients who developed resis-
tance after ICI treatment (online supplemental table 
S3). Thus, all samples after the ICIs were obtained in the 
resistance state. CD155 expression in resistant tumor cells 
significantly increased from the baseline as was observed 
in MEL04 (figure 6B,C). CD155 expression was particu-
larly increased in patients with high CD8+ T cell infiltra-
tion at the resistance state (≥82.8) (figure 6C), whereas 
it was comparable in other patients (<82.8). Altogether, 
the TIGIT/CD155 axis induces resistance to ICIs with 
the inflamed TME, including both primary and acquired 
resistance (‘inflamed resistance’).
DISCUSSION
ICIs such as anti- PD- 1 mAb and anti- CTLA- 4 mAb provide 
clinical benefits in many types of cancer including mela-
noma and lung cancer.5–7 However, many patients fail to 
respond primarily, and others acquire resistance after initial 
response, necessitating further understanding of the resis-
tance mechanisms.18 19 Neoantigens derived from somatic 
mutations induce a strong immune response, leading to an 
inflamed TME.10 15 16 ICIs can reinvigorate effector T cells in 
the inflamed TME, resulting in tumor regression.10–14 Thus, 
inflamed TME and high TMB are representative predictive 
biomarkers.10–16 However, MEL04 involved an inflamed TME 
and extremely high TMB but was resistant to ICIs. Thus, we 
focused on immune suppressive factors, especially co- in-
hibitory molecules. From RNA- seq data, we observed that 
CD155, a TIGIT ligand, was highly expressed in the MEL04 
cell line, compared with other ligands. TIGIT was also highly 
expressed in MEL04 tumor- infiltrating T cells compared 
with other co- inhibitory checkpoint molecules such as 
LAG- 3 and TIM- 3. Accordingly, in vitro assays using clinical 
samples, and in vivo mouse models showed that the TIGIT/
CD155 axis could mediate resistance to ICIs. Altogether, 
MEL04 was resistant to ICIs due to the TIGIT/CD155 axis 
despite having inflamed TME and extremely high TMB. In 
addition, we report for the first time that the TIGIT/CD155 
axis can contribute to such inflamed resistance, including 
both primary and acquired resistance, in another large mela-
noma cohort. Considering the contribution of the TIGIT/
CD155 axis to inflamed resistance, TIGIT blockade could 
be a potential candidate for combination treatment against 
inflamed resistant patients.
CD155 is an adhesion molecule expressed in tumor cells 
and tumor- associated myeloid cells that functions as a co- in-
hibitory molecule.24 25 CD155 interacts with a co- stimulatory 
molecule, CD226, and co- inhibitory molecules, TIGIT and 
CD96, resulting in either immune- cell activation or inhibi-
tion, respectively.25 26 Although TIGIT also binds to CD112, 
it exhibits the strongest affinity for CD155.25 26 Thus, the 
TIGIT/CD155 axis reportedly mediates immunosuppres-
sion in various immunological fields, including cancer 
immunology,40–44 therapeutic targeting of the TIGIT/
CD155 axis has demonstrated efficacy and synergistic activity 
with anti- PD- 1/PD- L1 mAb in preclinical tumor models,45 46 
and high expression of CD155 in tumor cells is associated 
with decreased sensitivity to ICIs in clinical samples.30 In 
addition, several studies have indicated the clinical signifi-
cance of TIGIT, including poor prognosis and resistance to 
ICIs.46–48 Compared with these studies, our study is valuable 
in that we validated the inflamed resistance using a consider-
able number of clinical samples, including both primary and 
acquired resistance, and its mechanisms using pairs of autol-
ogous tumor cell lines and TILs in addition to in vivo mouse 
models. Furthermore, we created an acquired resistance 
model using human clinical samples. In vivo mouse models, 
LAG- 3 and TIM- 3 are related to acquired resistance.22 Our 
model, using human clinical samples, clearly demonstrated 
that the TIGIT/CD155 axis induces acquired resistance to 
ICIs, in particular inflamed resistance, which was observed in 
MEL04 and another large melanoma cohort. That is, TIGIT 
expression in effector T cells increased via TCR signaling 
pathways, which can be activated by PD- 1 blockade,32 in 
the inflamed TME, and such TIGIT+ effector T cells were 
subsequently suppressed by CD155 expressed in tumor cells, 
leading to the survival of CD155- expressing tumor cells and 
resistance. In contrast, CD155 is reportedly regulated by 
nuclear factor-κB (NFκB) signaling pathways.49 Thus, such 
an inflammatory response in the TME could also induce 
CD155- mediated resistance. In addition, TIGIT is report-
edly a chronic- stimulated exhausted T cell marker, in addi-
tion to PD- 1.8 9 Accordingly, high expression of TIGIT can 
also be related to resistance to ICIs, such as CD155.30 47 48 
Furthermore, the expression in effector T cells and regu-
latory T cells reportedly induces resistance.47 48 From these 
findings, chronic stimulation can drive increased expression 
of TIGIT and CD155 and/or selection for cells expressing 
these proteins. Further research is warranted to elucidate 
the detailed mechanisms of resistance.
This study has some limitations. The number of human 
clinical samples in the functional assays was small because 
it is difficult to establish tumor cell lines, and both two resis-
tance samples were obtained at acquired resistance. Thus, to 
generalize our findings, we performed in vivo mouse exper-
iments. Furthermore, we validated the contribution of the 
TIGIT/CD155 axis to resistance in another large melanoma 
cohort, showing that the TIGIT/CD155 axis could induce 
inflamed resistance, including both primary and acquired 
resistance. While further research is warranted, we believe 
that the TIGIT/CD155 axis can generally induce inflamed 
resistance, including both primary and acquired resistance. 
In addition, these findings can be expanded beyond mela-
noma to other cancer types, such as lung cancer, although 
we analyzed only melanoma samples. Indeed, a randomized 
phase 2 trial of combination therapy with anti- PD- L1 mAb and 
anti- TIGIT mAb has demonstrated favorable efficacy against 
PD- L1 high lung cancer, which can reflect inflamed TME,50 
and a phase 3 trial is currently ongoing (NCT04294810). 
Acral and mucosal melanomas are dominant in Japan,34 
and our cohort included a considerable number of these 
types. While acral and mucosal melanomas reportedly 
have a non- inflamed TME with less efficacy of ICIs,35–37 a 
Japanese prospective observational study has shown that 
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anti- PD- 1 mAb exhibits similar efficacy against these types.34 
In our cohort, there was no significant difference in CD8+ 
T- cell infiltration or CD155 expression among melanoma 
types. While patients with acral or mucosal melanoma had 
a slightly shorter OS, multivariate analyses demonstrated 
that the melanoma type was not a prognostic factor. While 
larger research is required, it seems challenging to consider 
whether the melanoma type can reflect the immune status 
from our analyses.
In summary, we have shown that the TIGIT/CD155 axis 
contributes to resistance to ICIs in both in vitro functional 
assays using clinical samples and in vivo mouse models. 
CD155 was highly expressed in tumor cells from resistant 
patients, including both primary and acquired resistance, 
despite the inflame TME from another large melanoma 
cohort. TIGIT blockade therapies could be candidates 
for combination treatment against inflamed resistant 
patients. We propose the development of combination 
therapies with TIGIT blockade against resistant patients 
with inflamed TME and high TIGIT/CD155 expression.
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